ArticleInternational health2009
Caffeine for the management of apnea in preterm infants.
Article in International health, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 39 citations in OpenAlex.
- Pooled it
- Evidence-based interventions to reduce mortality among preterm and low-birthweight neonates in low-income and middle-income countries: a systematic review and meta-analysis.BMJ global health · 2021Pooled it
- Pharmacological treatment for apnoea of prematurity-the need for an individualised approach.Frontiers in pediatrics · 2025Review
- A landscape evaluation of caffeine citrate availability and use in newborn care across five low- and middle-income countries.PLOS global public health · 2024Article
- Effect of Oral Caffeine on Weaning from Mechanical Ventilation in Intubated ICU Patients.Tanaffos · 2023Article
- Specific Premature Groups Have Better Benefits When Treating Apnea With Caffeine Than Aminophylline/Theophylline.Frontiers in pediatrics · 2022Article
- Caffeine for the care of preterm infants in sub-Saharan Africa: a missed opportunity?BMJ global health · 2021Article
- Caffeine versus aminophylline in combination with oxygen therapy for apnea of prematurity: A retrospective cohort study.Experimental and therapeutic medicine · 2020Article
- [Safety and efficacy of caffeine use started at different time in preterm infants: a multicenter study in Jiangsu Province, China].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2020Article
- The efficacy and safety of two different doses of caffeine in respiratory function of preterm infants.Caspian journal of internal medicine · 2018Article
- A Pilot Randomized Controlled Trial of a New Supplementary Food Designed to Enhance Cognitive Performance during Prevention and Treatment of Malnutrition in Childhood.Current developments in nutrition · 2017Article
- Low dose aminophylline effectively decreases the risk of post-operative apnea in premature infants.Tanaffos · 2014Article
- Apnea of prematurity: from cause to treatment.European journal of pediatrics · 2011Review
- Prediction of pharmacokinetic values of two various dosages of caffeine in premature neonates with apnea.Indian journal of pharmacologyArticle
- Medication Repurposing in Pediatric Patients: Teaching Old Drugs New Tricks.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAGArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 2 countries.
Funding
Abstract
Considerable uncertainty persists regarding the efficacy and safety of methylxanthines (caffeine, theophylline - in intravenous form named aminophylline) for the prevention and treatment of infant apnea. To help inform national guideline development in Kenya we undertook structured literature searches to identify current evidence on caffeine therapy for infant apnea. Available evidence shows that caffeine is as effective as intravenous theophylline (aminophylline), but is safer and easier to give and has better therapeutic properties. It is therefore recommended for the treatment of apnea of prematurity. Caffeine is also the preferred drug if clinicians plan to provide apnea prophylaxis. As prematurity is likely to result in more than 1 million deaths a year, mostly in resource-poor settings, greater efforts need to be made to ensure interventions such as caffeine, currently unavailable in countries such as Kenya, are made more widely available.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.